Martínez SC

Language: Spanish
References: 9
Page: 1-6
PDF size: 273.05 Kb.

ABSTRACT

The tools with which they have currently are vaccines as primary prevention, is incorporating as a fundamental implementation and more early possible according to the availability and experience of each region or countries immersed in immunization programmes according to the burden and cost benefit to achieve expected immunity, screening diagnosis and treatment based on the serial of PAP with strong continuity bias will remain the cornerstone with or without vaccine It is the strategy of control and prevention program of early diagnostic improving techniques and approaches to all the female population with active sexuality, digital tools as the colposcopy, biopsy and procedures mini invasive help us preventive, predictive and healing diagnoses depending on the qualification and training of the colposcopistas. The criminalization that alerts us to the presence of papilloma virus of low and high grade is of valuable biological assistance for the prevention, currently taken valuation diagnosed with important

REFERENCES

1. Giraudo N, Discacciati V ,Bakalar K ,Basualdo N y Dreyer C. Barreras para el rastreo de cáncer de cuello uterino en la Ciudad de Buenos Aires. Archivos de Medicina Familiar y General.Volumen 3 Número 2 – 2006. pp 7-21. Disponible en URL: http://www.famfyg.org.ar/revista/revista_famfyg/volume n3_n2/investigacion_01.pdf (último acceso 14/06/08)..

2. González de Dios J, Buñuel Álvarez JC. Las conclusiones de los metaanálisis financiados por la industria farmacéutica deben ser interpretadas con precaución. Evid Pediatr. 2007;3:6.

3. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3384.

4. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915-23.

5. CDC´s Advisory Committee on Immunization Practices (ACIP). Summary report, Atlanta, Georgia [en línea][fecha de acceso: 15-I-2011]. Disponible en: http://www.cdc.gov/vaccines/recs/acip/downloads/minjun09. pdf

6. Martínez-González MA, Carlos S, De Irala J. Vacuna contra el virus del papiloma humano: razones para el optimismo y razones para la prudencia. Med Clin (Barc). 2008;131:256-63.

7. Koutsky L,and theFutureII study grup. Qudricvalentvacineagainst human papilomavirus to prevent hig-grade cervical lesions.N Engl JMed 2007;305:27

8. Matti Lehtinen yJoakim Dillner Nacional public HealthInstitute, Finlandia; who hpv LabNet GlobalRefernce Laboratory,Universidad de Lund, MalmO, Suecia

9. Bosch FX y cols. HPV Vaccines and Screening in the Prevention the Cervical Cancer. Vaccine 2006; 24(suppl3)